Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: How useful are prognostic indices in routine clinical practice?

被引:8
作者
Akman, F [1 ]
Cooper, RA [1 ]
Sen, M [1 ]
Tanriver, Y [1 ]
Kentli, S [1 ]
机构
[1] Dokuz Eylul Univ, Sch Med, Dept Radiat Oncol, TR-35340 Izmir, Turkey
关键词
high grade gliomas; prognostic index; survival;
D O I
10.1023/A:1016353614525
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although different prognostic indices for malignant gliomas have been developed, their validity outside of clinical trials has not been widely tested. The aim of this study was to determine whether the Medical Research Council (MRC) brain tumour prognostic index was able to stratify patients for survival managed in routine practice, and secondly to compare the results with our newly developed prognostic score which included tumour grade and only 3 prognostic groups. The MRC and the new prognostic index were calculated for a group of 119 adult patients with malignant glioma managed by surgical resection/biopsy and post-operative radiotherapy. For the MRC and new score, 6 and 3 prognostic groups were defined, respectively. For all patients median survival was 11 (2-66) months. The overall survival rate at 12 and 24 months were 43% and 18%, respectively. The MRC median and two-year survival rates were 14 months and 26% for a score of 1-10, 14 months and 27% for a score of 11-15, 13 months and 22% for a score of 16-20, 8 months and 10% for a score of 21-25, 8 months and 0% for those scoring 26-33. There was only one patient in the 34-38 group. For the new prognostic index, median and two-year survival rates were respectively 16 and 26%; 12 and 23%; 8 and 7% for the good, intermediate and poor prognostic groups. Both indices were significant factors for survival in univariate analysis (MRC index, p = 0.0089, new index p = 0.0002), but not in multivariate analysis. Both the MRC and our newly devised prognostic score were able to separate patients into good and poor prognostic groups, which may aid in treatment decisions, although there was less differentiation between the MRC groups especially over the first year. Both scores use routinely available factors. However, inclusion of tumour grade in the new score may be an advantage over the MRC index.
引用
收藏
页码:39 / 47
页数:9
相关论文
共 40 条
[1]   Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma [J].
Anders, K ;
Grabenbauer, GG ;
Schuchardt, U ;
Fahlbusch, R ;
Fietkau, R ;
Sauer, R ;
Krauseneck, P .
JOURNAL OF NEURO-ONCOLOGY, 2000, 48 (01) :63-73
[2]  
[Anonymous], 1983, Br J Radiol, V56, P673
[3]   POTENTIAL PITFALLS IN THE USE OF P-VALUES AND IN INTERPRETATION OF SIGNIFICANCE LEVELS [J].
BECKBORNHOLDT, HP ;
DUBBEN, HH .
RADIOTHERAPY AND ONCOLOGY, 1994, 33 (02) :171-176
[4]   A MEDICAL-RESEARCH-COUNCIL TRIAL OF 2 RADIOTHERAPY DOSES IN THE TREATMENT OF GRADE-3 AND GRADE-4 ASTROCYTOMA [J].
BLEEHEN, NM ;
STENNING, SP .
BRITISH JOURNAL OF CANCER, 1991, 64 (04) :769-774
[5]   Modifying radical radiotherapy in high grade gliomas; Shortening the treatment time through acceleration [J].
Brada, M ;
Sharpe, G ;
Rajan, B ;
Britton, J ;
Wilkins, PR ;
Guerrero, D ;
Mines, F ;
Traish, D ;
Ashley, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (02) :287-292
[6]   Accelerated hyperfractionated radiotherapy for malignant gliomas [J].
Buatti, JM ;
Marcus, RB ;
Mendenhall, WM ;
Friedman, WA ;
Bova, FJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (04) :785-792
[7]  
CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO
[8]  
2-2
[9]  
CURRAN WJ, 1992, J NEURO-ONCOL, V12, P219
[10]   MISONIDAZOLE COMBINED WITH HYPERFRACTIONATION IN THE MANAGEMENT OF MALIGNANT GLIOMA [J].
FULTON, DS ;
URTASUN, RC ;
SHIN, KH ;
GEGGIE, PHS ;
THOMAS, H ;
MULLER, PJ ;
MOODY, J ;
TANASICHUK, H ;
MIELKE, B ;
JOHNSON, E ;
CURRY, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (09) :1709-1712